ERBB2 and cancer: The DESTINY-Gastric01 phase II trial in patients with HER2 positive gastric and GOJ cancers who had received at least two lines of prior treatment (including trastuzumab) demonstrated significantly superior objective response rates (ORRs) and OS with T-DXd therapy compared to physician’s choice chemotherapy (51% vs. 14%, P < 0.001 and 12.5 months vs. 8.4 months; HR for death, 0.59, P = 0.01 respectively) [34].